Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study.

MLA

Chalmers, James D., et al. “Cathepsin C (Dipeptidyl Peptidase 1) Inhibition in Adults with Bronchiectasis: AIRLEAF®, a Phase II Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study.” The European Respiratory Journal, Oct. 2024. EBSCOhost, https://doi.org/10.1183/13993003.01551-2024.

APA

Chalmers, J. D., Shteinberg, M., Mall, M. A., O’Donnell, A. E., Watz, H., Gupta, A., Frahm, E., Eleftheraki, A., Rauch, J., Chotirmall, S. H., Armstrong, A. W., Eickholz, P., Hasegawa, N., Sauter, W., & McShane, P. J. (2024). Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study. The European Respiratory Journal. https://doi.org/10.1183/13993003.01551-2024

Chicago

Chalmers, James D, Michal Shteinberg, Marcus A Mall, Anne E O’Donnell, Henrik Watz, Abhya Gupta, Edith Frahm, et al. 2024. “Cathepsin C (Dipeptidyl Peptidase 1) Inhibition in Adults with Bronchiectasis: AIRLEAF®, a Phase II Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study.” The European Respiratory Journal, October. doi:10.1183/13993003.01551-2024.